Revolution Medicines, Inc. (RVMD) — Financial statements
Income statement, balance sheet, and cash flow for Revolution Medicines, Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 0.00 | 0.00↓100.0% | 12↓67.3% | 35↑20.4% | 29 | |
| Cost of Revenue | 17 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Gross Profit | -17 | 0.00↓100.0% | 12↓67.3% | 35↑20.4% | 29 | |
| Operating Expenses | ||||||
| R&D Expenses | 979↑65.3% | 592↑40.0% | 423↑67.2% | 253↑35.4% | 187 | |
| General & Administrative Expenses | 187↑92.3% | 97↑28.7% | 76↑86.3% | 41↑33.3% | 30 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 187↑92.3% | 97↑28.7% | 76↑86.3% | 41↑33.3% | 30 | |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Operating Expenses | 1,166↑69.1% | 690↑38.2% | 499↑69.8% | 294↑35.1% | 217 | |
| Total Costs & Expenses | 1,182↑71.5% | 690↑38.2% | 499↑69.8% | 294↑35.1% | 217 | |
| Operating Results | ||||||
| Operating Income | -1,182↓71.5% | -690↓41.5% | -487↓88.6% | -258↓37.4% | -188 | |
| Depreciation & Amortization | 17↑40.0% | 12↑27.0% | 9↓3.6% | 10↑31.7% | 7 | |
| EBITDA | -1,091↓60.9% | -678↓41.8% | -478↓92.2% | -249↓38.3% | -180 | |
| EBIT | -1,107↓60.6% | -690↓41.5% | -487↓88.6% | -258↓38.1% | -187 | |
| Interest & Other Income | ||||||
| Net Interest Income | 66↓23.5% | 87↑84.2% | 47↑415.4% | 9↑898.3% | 0.92 | |
| Interest Income | 91↑4.4% | 87↑83.0% | 47↑418.7% | 9↑885.4% | 0.93 | |
| Interest Expense | 24 | 0.00↓100.0% | 0.30 | 0.00↓100.0% | 0.01 | |
| Non-Operating Income | -75 | 0.00 | 0.00 | 0.00↑100.0% | -0.93 | |
| Other Income / Expenses | 51↓42.4% | 89↑87.5% | 47↑416.6% | 9↑898.3% | 0.92 | |
| Income Before Tax | -1,131↓88.3% | -601↓36.6% | -440↓76.6% | -249↓33.2% | -187 | |
| Income Tax Expense | 0.00↑100.0% | -0.75↑78.6% | -4↓739.0% | -0.42 | 0.00 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -1,131↓88.5% | -600↓37.5% | -436↓75.5% | -249↓32.9% | -187 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -1,131↓88.5% | -600↓37.5% | -436↓75.5% | -249↓32.9% | -187 | |
| Bottom-Line Net Income | -1,131↓88.5% | -600↓37.5% | -436↓75.5% | -249↓32.9% | -187 | |
| EPS (Basic) | -5.95↓66.2% | -3.58↑7.3% | -3.86↓25.3% | -3.08↓24.7% | -2.47 | |
| EPS (Diluted) | -5.95↓66.2% | -3.58↑7.3% | -3.86↓25.3% | -3.08↓24.7% | -2.47 | |
| Weighted Average Shares | 190↑13.3% | 168↑48.2% | 113↑40.3% | 81↑10.7% | 73 | |
| Weighted Average Diluted Shares | 190↑13.3% | 168↑48.2% | 113↑40.3% | 81↑10.7% | 73 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.